The presence of human positive CD4 cells in the synovium of the APS treatment groups with cells (APS, CD3+ sorted from APS, and CD45+ sorted from APS) demonstrates cell persistence and the durability of the cell fraction that may be important for APS treatment outcomes (Fig. 4d). This evidence concerns the gene CD4 and autoimmune polyendocrinopathy.